Relevance of a "dear Doctor letter" to alert healthcare providers to new recommendations for vitamin D administration

European Journal of Clinical Pharmacology

Volumn 67, Issue 7, 2011, Pages 681-686

  Théophile, Hélène ^a,b,c   Miremont Salamé, Ghada ^a,b,c   Robinson, Philip ^a   Moore, Nicholas ^a,b,c   Bégaud, Bernard ^a,b,c   Haramburu, Françoise ^a,b,c  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b INSERM U657   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

Administration; Communication; Evaluation studies as topic; Oral; Safety warning; Vitamin D

Indexed keywords

VITAMIN D;

ARTICLE; CROSS-SECTIONAL STUDY; DRUG INFORMATION; FRANCE; GENERAL PRACTITIONER; HEALTH PERSONNEL ATTITUDE; HUMAN; INFORMATION DISSEMINATION; PEDIATRICIAN; PHARMACIST ATTITUDE; PHYSICIAN ATTITUDE; POSTAL MAIL; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; VITAMIN SUPPLEMENTATION;

ADMINISTRATION, ORAL; ADVERSE DRUG REACTION REPORTING SYSTEMS; BONE DENSITY CONSERVATION AGENTS; COMMUNICATION; CONSUMER PRODUCT SAFETY; CROSS-SECTIONAL STUDIES; DRUG INTERACTIONS; DRUG LABELING; HEALTH PERSONNEL; HUMANS; INFANT; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES; VITAMIN D;

EID: 79959692377     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1055-y     Document Type: Article

References (30)

1. EMEA Guideline on riskmanagement systems formedicinal products for human use (CHMP) (2005) Available at: http://www.ema.europa. eu/docs/en-GB/document- library/Regulatory-and-procedural- guideline/2009/2010/WC500004888.pdf. Accessed Feb 2011
2. Volume 9A of The Rules Governing Medicinal Products in the European Union (2006) Guidelines on Pharmacovigilance for Medicinal Products for Human Use (2008). Available at: http://ec. europa.eu/health/files/pharmacos/docs/doc2005/ 2012-2005/draft-of- volume-2009a-2012-2005-en.pdf. Accessed Feb 2011
3. Lettre aux prescripteurs adressée par les laboratoires Crinex (2006) Information importante de pharmacovigilance Uvestérol Vitamine ADEC, solution buvable Uvestérol D 1500UI/mL, solution buvable. Available at: http://www.afssaps.fr/content/ download/11927/142830/version/142832/file/ ddl-uvesterol.pdf. Accessed Feb 2011
4. Communiqué de presse de l'AFSSAPS (2006) Nouvelles recommandations d'administration pour Uvestérol vitaminé ADEC et Uvestérol D 1500UI/mL. http://www.afssaps.fr/Infos-desecurite/ Communiques-de-presse/ Nouvelles-recommandations-dadministration- pour-Uvesterol-Vitamine-ADEC-et- Uvesterol-D- 1500UI-mL. Accessed Feb 2011
5. Mol PG, Straus SM, Piening S, de Vries JT, de Graeff PA, Haaijer-Ruskamp FM (2010) A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009. Drug Saf 33:463-474 4. doi:10.2165/11532840-000000000-00000 6. MHRA Safety warnings and messages for medicines. Available at:http://www.mhra. gov.uk/Safetyinformation. Accessed Feb 2011
6. AFSSAPS (Lettre aux professionels de santé). Available at: http:// www.afssaps.fr/Infos-de-securite/Lettres-aux-professionnels-desante. Accessed Feb 2011
7. van Grootheest AC, Edwards IR (2002) Labelling and 'Dear Doctor' letters: are they noncommittal? Drug Saf 25:1051-1055
8. Sondergaard J, Andersen M, Vach K, Kragstrup J, Maclure M, Gram LF (2002) Detailed postal feedback about prescribing to asthma patients combined with a guideline statement showed no impact: a randomised controlled trial. Eur J Clin Pharmacol 58:127-132. doi:10.1007/s00228-002-0454-5
9. Smalley W, Shatin D, Wysowski DK, Gurwitz J, Andrade SE, Goodman M, Chan KA et al (2000) Contraindicated use of cisapride: impact of food and drug administration regulatory action. JAMA 284:3036-3039 (Pubitemid 32014741)
10. Shatin D, Gardner JS, Stergachis A, Blough D, Graham D (2005) Impact of mailed warning to prescribers on the co-prescription of tramadol and antidepressants. Pharmacoepidemiol Drug Saf 14:149-154 (Pubitemid 40360767)
11. Hurault C, Lacroix I, Bourrel R, Montastruc JL, Damase-Michel C (2008) Writing and dispensing of NSAID prescriptions in late pregnancy: impact of health authorities' advice. Presse Méd 37:767-774
12. Graham DJ, Drinkard CR, Shatin D, Tsong Y, Burgess MJ (2001) Liver enzyme monitoring in patients treated with troglitazone. JAMA 286:831-833 (Pubitemid 33015577)
13. Cluxton RJ Jr, Li Z, Heaton PC, Weiss SR, Zuckerman IH, Moomaw CJ, Hsu VD et al (2005) Impact of regulatory labeling for troglitazone and rosiglitazone on hepatic enzyme monitoring compliance: findings from the state of Ohio medicaid program. Pharmacoepidemiol Drug Saf 14:1-9 (Pubitemid 40089572)
14. Bahri P (2010) Public pharmacovigilance communication: a process calling for evidence-based, objective-driven strategies. Drug Saf 33:1065-1079. doi:10.2165/11539040-000000000- 00000
15. Guo JJ, Curkendall S, Jones JK, Fife D, Goehring E, She D (2003) Impact of cisapride label changes on codispensing of contraindicated medications. Pharmacoepidemiol Drug Saf 12:295-301 (Pubitemid 36700605)
16. Victorri-Vigneau C, Marais M, Veyrac G, Chaslerie A, Pivette J, Jolliet P (2007) Reactivity and communication of Health Authorities toward health professionals: a public health priority. Therapie 62:513-517
17. Weatherby LB, Walker AM, Fife D, Vervaet P, Klausner MA (2001) Contraindicated medications dispensed with cisapride: temporal trends in relation to the sending of 'Dear Doctor' letters. Pharmacoepidemiol Drug Saf 10:211-218
18. Sturkenboom MC, de Jong-van den Berg LT, Cornel MC, Stricker BH, Wesseling H (1994) Communicating a drug alert. A case study on acitretin in The Netherlands. Eur J Clin Pharmacol 47:125-132
19. Volume 9A of The Rules Governing Medicinal Products in the European Union (2008) Guidelines on Pharmacovigilance for Medicinal Products for Human Use. Available at; http://ec.europa. eu/health/files/eudralex/vol-9/pdf/vol9a-09- 2008-en.pdf. Accessed Feb 2011
20. Sanfelix-Gimeno G, Cervera-Casino P, Peiro S, Lopez-Valcarcel BG, Blazquez A, Barbera T (2009) Effectiveness of safety warnings in atypical antipsychotic drugs: an interrupted time-series analysis in Spain. Drug Saf 32:1075-108. doi:10.2165/ 11316520-000000000-00000
21. Carlson AM, Morris LS (1996) Coprescription of terfenadine and erythromycin or ketoconazole: an assessment of potential harm. J Am Pharm Assoc Wash NS36:263-269
22. Jones JK, Fife D, Curkendall S, Goehring E Jr, Guo JJ, Shannon M (2001) Coprescribing and codispensing of cisapride and contraindicated drugs. JAMA 286:1607-1609 (Pubitemid 33010285)
23. Lee LY, Kortepeter CM, Willy ME, Nourjah P (2008) Drug-risk communication to pharmacists: assessing the impact of risk-minimization strategies on the practice of pharmacy. J Am Pharm Assoc 48:494-500
24. Wilkinson JJ, Force RW, Cady PS (2004) Impact of safety warnings on drug utilization: marketplace life span of cisapride and troglitazone. Pharmacotherapy 24:978-986 (Pubitemid 39025197)
25. EMEA/CPMP (2005)Working Group with Patients Organisations. Outcome of discussions: recommendations and proposals for action. Available at: http://www.ema.europa.eu/ema/index.jsp? curl=pages/partners-and-networks/ document-listing/document- listing-000235.jsp&murl=menus/partners-and- networks/partners- and-networks.jsp&mid=WC0b01ac05800aa3cb&jsenabled= true#. Accessed Feb 2011
26. Orme M (2002) The Erice Statement on drug advertising to consumers. Eur J Clin Pharmacol 58:S106-108
27. Hugman B, Edwards IR (2006) The challenge of effectively communicating patient safety information. Expert Opin Drug Saf 5:495-499. doi:10.1517/ 14740338.5.4.495 (Pubitemid 44468447)
28. Commission nationale de l'informatique et des libertés. Available at: http://www.cnil.fr. Accessed February 2011.
29. Power A, Johnson BJ, Diack HL, McKellar S, Stewart D, Hudson SA (2008) Scottish pharmacists' views and attitudes towards continuing professional development. Pharm World Sci 30:136-143. doi:10.1007/s11096-007-9156-5 (Pubitemid 350172661)
30. Kaestner SA, Sewell GJ (2009) A national survey investigating UK prescribers' opinions on chemotherapy dosing and 'dose-banding'. Clin Oncol R Coll Radiol 21:320-328. doi:10.1016/j. clon.2008.12.004